UBS Maintains Buy on Adient, Lowers Price Target to $23

Benzinga Newsdesk www.benzinga.com Negative 59.9%

Neg 59.9% Neu 0% Pos 0%

UBS analyst Joseph Spak maintains Adient (NYSE:ADNT) with a Buy and lowers the price target from $29 to $23.

Comments

No comments yet. Be the first!